Brain uptake and distribution of the potential memory enhancer CL 275,838 and its main metabolites in rats: relationship between brain concentrations and in vitro potencies on neurotransmitter mechanisms

S. Caccia, S. Confalonieri, G. Guiso, P. Bernasconi, A. Cagnotto, M. Skorupska, T. Mennini

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

The kinetics, brain uptake and distribution of CL 275,838, a potential memory enhancer, and its main metabolites (II and IV) were evaluated in rats after intraperitoneal doses of 5, 10 and 20 mg/kg. Brain maximum concentrations (Cmax) of the three compounds after pharmacologically active doses were then related to the in vitro concentrations affecting some monoaminergic and amino acid receptor sites to examine the relative importance of these neurotransmitter systems in the pharmacological actions of CL 275,838. After 10 mg/kg CL 275,838, the unchanged compound rapidly entered the brain and distributed almost uniformly in various regions inside the blood-brain barrier. Its disappearance from brain and plasma was almost parallel with a comparable elimination half-life (t1/2) of about 2 h. Metabolite II entered the brain and equilibrated with plasma more slowly than the parent compound, achieving mean Cmax (0.2 μM) within 3 h of dosing. Metabolite IV was rapidly detected in rat brain but hardly amounted to 10% (0.1 μM) of the parent compound Cmax (1 μM). There was a linear relationship between dose and plasma and brain concentrations of the three compounds up to 20 mg/kg CL 275,838. At micromolar concentrations the parent compound had affinity for serotonin (5-HT) uptake sites, 5-HT2 and dopamine (DA2) receptors. Only at much higher concentrations than those achieved in vivo after pharmacologically active doses did it increase the binding of3H-glutamate to NMDA (N-methyl-d-aspartate) receptors. Metabolite II had a similar neurochemical profile. Metabolite IV had no affinity for these neurotransmitter systems, except for benzodiazepine (BDZ) receptor sites where it interacts with micromolar affinity behaving, however, as an agonist as determined by the GABA ratio. Although the effect on NMDA is compatible with favourable effects on memory, it is unlikely that it is involved in the ability of CL 275,838 to attenuate the impairment of a passive avoidance task caused by drugs or aging in rats.

Original languageEnglish
Pages (from-to)502-508
Number of pages7
JournalPsychopharmacology
Volume115
Issue number4
DOIs
Publication statusPublished - Aug 1994

Fingerprint

Neurotransmitter Agents
Brain
Serotonin
Amino Acid Receptors
Aptitude
Dopamine Receptors
GABA-A Receptors
In Vitro Techniques
CL 275838
Blood-Brain Barrier
Aspartic Acid
gamma-Aminobutyric Acid
Half-Life
Glutamic Acid
Pharmacology
Pharmaceutical Preparations

Keywords

  • Brain uptake and distribution
  • CL 275,838
  • Kinetics
  • Metabolism
  • Neurotransmitter receptor affinities

ASJC Scopus subject areas

  • Pharmacology

Cite this

Brain uptake and distribution of the potential memory enhancer CL 275,838 and its main metabolites in rats : relationship between brain concentrations and in vitro potencies on neurotransmitter mechanisms. / Caccia, S.; Confalonieri, S.; Guiso, G.; Bernasconi, P.; Cagnotto, A.; Skorupska, M.; Mennini, T.

In: Psychopharmacology, Vol. 115, No. 4, 08.1994, p. 502-508.

Research output: Contribution to journalArticle

@article{f83df6263ae248c4b065df277e18a274,
title = "Brain uptake and distribution of the potential memory enhancer CL 275,838 and its main metabolites in rats: relationship between brain concentrations and in vitro potencies on neurotransmitter mechanisms",
abstract = "The kinetics, brain uptake and distribution of CL 275,838, a potential memory enhancer, and its main metabolites (II and IV) were evaluated in rats after intraperitoneal doses of 5, 10 and 20 mg/kg. Brain maximum concentrations (Cmax) of the three compounds after pharmacologically active doses were then related to the in vitro concentrations affecting some monoaminergic and amino acid receptor sites to examine the relative importance of these neurotransmitter systems in the pharmacological actions of CL 275,838. After 10 mg/kg CL 275,838, the unchanged compound rapidly entered the brain and distributed almost uniformly in various regions inside the blood-brain barrier. Its disappearance from brain and plasma was almost parallel with a comparable elimination half-life (t1/2) of about 2 h. Metabolite II entered the brain and equilibrated with plasma more slowly than the parent compound, achieving mean Cmax (0.2 μM) within 3 h of dosing. Metabolite IV was rapidly detected in rat brain but hardly amounted to 10{\%} (0.1 μM) of the parent compound Cmax (1 μM). There was a linear relationship between dose and plasma and brain concentrations of the three compounds up to 20 mg/kg CL 275,838. At micromolar concentrations the parent compound had affinity for serotonin (5-HT) uptake sites, 5-HT2 and dopamine (DA2) receptors. Only at much higher concentrations than those achieved in vivo after pharmacologically active doses did it increase the binding of3H-glutamate to NMDA (N-methyl-d-aspartate) receptors. Metabolite II had a similar neurochemical profile. Metabolite IV had no affinity for these neurotransmitter systems, except for benzodiazepine (BDZ) receptor sites where it interacts with micromolar affinity behaving, however, as an agonist as determined by the GABA ratio. Although the effect on NMDA is compatible with favourable effects on memory, it is unlikely that it is involved in the ability of CL 275,838 to attenuate the impairment of a passive avoidance task caused by drugs or aging in rats.",
keywords = "Brain uptake and distribution, CL 275,838, Kinetics, Metabolism, Neurotransmitter receptor affinities",
author = "S. Caccia and S. Confalonieri and G. Guiso and P. Bernasconi and A. Cagnotto and M. Skorupska and T. Mennini",
year = "1994",
month = "8",
doi = "10.1007/BF02245574",
language = "English",
volume = "115",
pages = "502--508",
journal = "Psychopharmacology",
issn = "0033-3158",
publisher = "Springer Verlag",
number = "4",

}

TY - JOUR

T1 - Brain uptake and distribution of the potential memory enhancer CL 275,838 and its main metabolites in rats

T2 - relationship between brain concentrations and in vitro potencies on neurotransmitter mechanisms

AU - Caccia, S.

AU - Confalonieri, S.

AU - Guiso, G.

AU - Bernasconi, P.

AU - Cagnotto, A.

AU - Skorupska, M.

AU - Mennini, T.

PY - 1994/8

Y1 - 1994/8

N2 - The kinetics, brain uptake and distribution of CL 275,838, a potential memory enhancer, and its main metabolites (II and IV) were evaluated in rats after intraperitoneal doses of 5, 10 and 20 mg/kg. Brain maximum concentrations (Cmax) of the three compounds after pharmacologically active doses were then related to the in vitro concentrations affecting some monoaminergic and amino acid receptor sites to examine the relative importance of these neurotransmitter systems in the pharmacological actions of CL 275,838. After 10 mg/kg CL 275,838, the unchanged compound rapidly entered the brain and distributed almost uniformly in various regions inside the blood-brain barrier. Its disappearance from brain and plasma was almost parallel with a comparable elimination half-life (t1/2) of about 2 h. Metabolite II entered the brain and equilibrated with plasma more slowly than the parent compound, achieving mean Cmax (0.2 μM) within 3 h of dosing. Metabolite IV was rapidly detected in rat brain but hardly amounted to 10% (0.1 μM) of the parent compound Cmax (1 μM). There was a linear relationship between dose and plasma and brain concentrations of the three compounds up to 20 mg/kg CL 275,838. At micromolar concentrations the parent compound had affinity for serotonin (5-HT) uptake sites, 5-HT2 and dopamine (DA2) receptors. Only at much higher concentrations than those achieved in vivo after pharmacologically active doses did it increase the binding of3H-glutamate to NMDA (N-methyl-d-aspartate) receptors. Metabolite II had a similar neurochemical profile. Metabolite IV had no affinity for these neurotransmitter systems, except for benzodiazepine (BDZ) receptor sites where it interacts with micromolar affinity behaving, however, as an agonist as determined by the GABA ratio. Although the effect on NMDA is compatible with favourable effects on memory, it is unlikely that it is involved in the ability of CL 275,838 to attenuate the impairment of a passive avoidance task caused by drugs or aging in rats.

AB - The kinetics, brain uptake and distribution of CL 275,838, a potential memory enhancer, and its main metabolites (II and IV) were evaluated in rats after intraperitoneal doses of 5, 10 and 20 mg/kg. Brain maximum concentrations (Cmax) of the three compounds after pharmacologically active doses were then related to the in vitro concentrations affecting some monoaminergic and amino acid receptor sites to examine the relative importance of these neurotransmitter systems in the pharmacological actions of CL 275,838. After 10 mg/kg CL 275,838, the unchanged compound rapidly entered the brain and distributed almost uniformly in various regions inside the blood-brain barrier. Its disappearance from brain and plasma was almost parallel with a comparable elimination half-life (t1/2) of about 2 h. Metabolite II entered the brain and equilibrated with plasma more slowly than the parent compound, achieving mean Cmax (0.2 μM) within 3 h of dosing. Metabolite IV was rapidly detected in rat brain but hardly amounted to 10% (0.1 μM) of the parent compound Cmax (1 μM). There was a linear relationship between dose and plasma and brain concentrations of the three compounds up to 20 mg/kg CL 275,838. At micromolar concentrations the parent compound had affinity for serotonin (5-HT) uptake sites, 5-HT2 and dopamine (DA2) receptors. Only at much higher concentrations than those achieved in vivo after pharmacologically active doses did it increase the binding of3H-glutamate to NMDA (N-methyl-d-aspartate) receptors. Metabolite II had a similar neurochemical profile. Metabolite IV had no affinity for these neurotransmitter systems, except for benzodiazepine (BDZ) receptor sites where it interacts with micromolar affinity behaving, however, as an agonist as determined by the GABA ratio. Although the effect on NMDA is compatible with favourable effects on memory, it is unlikely that it is involved in the ability of CL 275,838 to attenuate the impairment of a passive avoidance task caused by drugs or aging in rats.

KW - Brain uptake and distribution

KW - CL 275,838

KW - Kinetics

KW - Metabolism

KW - Neurotransmitter receptor affinities

UR - http://www.scopus.com/inward/record.url?scp=0027991280&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027991280&partnerID=8YFLogxK

U2 - 10.1007/BF02245574

DO - 10.1007/BF02245574

M3 - Article

C2 - 7871095

AN - SCOPUS:0027991280

VL - 115

SP - 502

EP - 508

JO - Psychopharmacology

JF - Psychopharmacology

SN - 0033-3158

IS - 4

ER -